Catalyst
Slingshot members are tracking this event:
Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BLPH |
|
|
Additional Information
Bellerophon has also enrolled the first subject in a Phase 2 trial evaluating the safety and efficacy of the INOpulse delivery system in patients with pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) in collaboration with Professor W. DeBacker, MD,Director Department of Pulmonary Medicine, University Hospital and University of Antwerp.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pulmonary Arterial Hypertension, Inovation-1 Phase 3, Pah